Danielle George - All Headline News Staff Reporter

The new vaccine, made by GlaxoSmithKline Plc, will attempt to fill the void left after rival Chiron Corp. lost its license and could not deliver half the anticipated U.S. supply during the 2004-2005 flu season

Chiron Corp. says Wednesday it expects to provide a vaccine for the 2005-2006 flu season after a recent favorable inspection of the plant by U.S. regulators.

The company postponed U.S. sales of its flu vaccine last year due to contamination problems at its plant in England, which led to the withdrawal of its manufacturing license for Fluvirin last October

Chiron Corp. says on Wednesday that it expects to provide a vaccine for the 2005-2006 flu season after a recent favorable inspection of the plant by U.S. regulators, reports Reuters

The company had to postpone U.S. sales of its flu vaccine last year due to contamination problems at its plant in England, which led to the withdrawal of its manufacturing license for Fluvirin last October

An international team of scientists determines the three-dimensional molecular structure of a promising malaria-vaccine component.

The team hopes to produce a successful vaccine for the disease, which currently infects approximately 400 million people worldwide, killing about 2 million of them each year

Yvonne Lee - All Headline News Staff Reporter

Baltimore, MD (AP) - Chinese health officials are partnering up with a U.S. institute to battle AIDS in a country that officials fear will see a tenfold increase in HIV infection over the next five years